European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE

100% Bacteria free eggs for use in production of human and animal vaccines

Periodic Reporting for period 2 - OvaVAx (100% Bacteria free eggs for use in production of human and animal vaccines)

Período documentado: 2020-09-01 hasta 2021-11-30

In excess of 1 bn fertilised specific pathogen free (SPF) chicken eggs are used annually in vaccine manufacture, globally. SPF is the term that is used to describe eggs, which are confirmed to be free of various infectious agents e.g. bacteria and viruses. The embryo in the egg is used to grow the virus, the basis of the development and production of vaccines. Globally, there is a world shortage of ‘high grade’ eggs for vaccine manufacture and ongoing supply and contamination issues dictate a need for a superior product. Currently, all eggs used in vaccine manufacture, even those of the highest SPF grade, carry bacteria on the shell and 10-20% of eggs carry bacteria inside the shell. Internalised bacteria cannot be removed without damaging the embryo, rendering it of no use for vaccine production.
Bacterial contamination occurs because the eggshell may absorb contaminating bacteria, from external sources. An eggshell is porous to facilitate gaseous exchange by the growing embryo. The pores of the eggshell are vulnerable to bacterial ingress during laying and for approximately 5 minutes after the egg is laid. Unlike mammals, where the digestive tract is separate from the reproductive tract, in poultry, the reproductive tract merges with the digestive tract, in the cloaca, and there is a single point of exit from the hen for eggs and faeces. This results in the porous egg coming in contact with the chicken’s faeces prior to being laid and consequent contamination of 10-20% of the eggs within the shell occurs. Detection of infectious agents relies on microbiological monitoring but the 4-week lag time required to confirm the presence of infection in the SPF eggs, means that infected eggs will have already been used in vaccine production, causing rejections of batches of vaccines, delays to market and to patients. The cost of a rejected batch of vaccine can be up to $480,000 with annual losses of $35 million confirmed by one large customer visited during our extensive market research. Ovagen (OGL), in its proof of principle work, addressed this problem with its world’s first innovative disruptive patented technology of 100% bacteria-free eggs, also referred to as Germ Free (GF).
The World Health Organisation (WHO) in July 2019 set a target to make vaccination available to everyone, everywhere by 2030. Furthermore, The United Nations Transforming Our World, 2030 Agenda for Sustainable Development clearly states in goal 3.b the support for research and development of vaccines for the communicable and non-communicable diseases that primarily affect developing countries. However, in order to achieve this target of universal access to vaccines, a fundamental re-evaluation of aspects of current vaccine manufacturing processes is required. The COVID-19 global pandemic has highlighted the urgent need for access to innovative and disruptive technologies that will enable rapid manufacture of vaccines to prevent and control emerging diseases.
Societal benefits from our project are improved availability of vaccines and cost to health-services (from production efficiency and improved yield) for immunisation programmes to protect populations from disease outbreaks; clean water and vaccines are described by WHO as having the greatest impacts on human health.
An additional benefit from our project is that the use of GF eggs vs SPF eggs in vaccine production will enable vaccine manufacturers to get vaccines faster to market, at lower cost and improved quality, in greater quantities due to a lower batch rejection rate and a higher viral yield. This will bring significant benefits to populations globally by making available quality vaccines to prevent disease with the associated social and public health benefits. GF eggs will be a game-changer for vaccine health economics.
The overall objective of this project was to radically transform the way that egg based vaccines are manufactured globally and to offer an additional solution to the rapid development and manufacture of vaccines in the case of future pandemics.
Ovagen successfully achieved all of the objectives of the OvaVax project and developed the world’s first GF flock of birds and produced the world’s first GF eggs for use in vaccine manufacture and cutting edge research. Systems perfected during the project included the incubation and hatching of GF eggs, the design and functionality of GF avian surgical, hatching and production isolators and the sterilisation process of GF isolators including a robust environmental monitoring assessment to maintain their GF status.
A bespoke temperature controlled packaging system was designed and successfully trialled with customers.
A new website was developed with increased online presence on social media.
OGL successfully launched its commercial GF egg offering at the World Vaccine Conference (WVC) in Barcelona in October 2021.
Ovagen benefited from EU business coaching in Lean Manufacturing, Sales & Marketing and Strategic Management which had a positive effect on delivering the project and in developing robust marketing and strategic plans.

The company benefited enormously from Horizon 2020 SME Instrument Phase 2 funding which allowed the business progress from proof of concept to the development of the world’s first GF avian flock and GF eggs for customer evaluations. A multi skilled talented team is in place poised for scale up and commercialisation of the business.

The Project results will be disseminated through many platforms including:
(i) The OGL website, LinkedIn, videos, webinars/presentations with customers etc.
(ii) A Press Release in conjunction with Enterprise Ireland in Q1 2022
(iii) Presentations and attendance at the European and USA WVC’s in 2022 and relevant meetings/fora.
(iv) Publication in relevant scientific & commercial journals.
In current vaccine manufacturing processes, state of the art/best practice is to use SPF eggs. However, these SPF eggs are not free of bacterial contamination. The key output of this project was the establishment of a flock of GF hens that produce GF eggs for supply to vaccine manufacturers.
This interdisciplinary project will substantially transform how egg based vaccines are produced beyond the current state of the art by fundamentally improving the source material used in vaccine manufacture and replacing it with a superior product resulting in supply chain improvement for vaccine producers. This will radically transform the way egg based vaccines are manufactured globally and ensure rapid access to vaccines to prevent disease particularly in the case of global pandemics.
Low interferon levels in GF eggs are hypothesised to increase viral yield per egg. If proven, for specific critical viruses of significance to vaccine manufacturers this will have significant implications for vaccine production i.e. reduced cost of vaccines and enhanced global availability and GF eggs will exponentially increase vaccine yields for manufacturers and greatly enhance the value of this disruptive technology.
The OvaVax project has successfully advanced the research beyond the current state of the art.